Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

Mark P. van Opijnen, Marike L.D. Broekman, Filip Y.F. de Vos*, Edwin Cuppen, Jacobus J.M. van der Hoeven, Myra E. van Linde, Annette Compter, Laurens V. Beerepoot, Martin J. van den Bent, Maaike J. Vos, Helle Brit Fiebrich, Johan A.F. Koekkoek, Ann Hoeben, Kuan H. Kho, Chantal M.L. Driessen, Hanne Rinck Jeltema, Pierre A.J.T. Robe, Sybren L.N. Maas

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
19 Downloads (Pure)


Background: Glioblastoma (GBM), the most common glial primary brain tumour, is without exception lethal. Every year approximately 600 patients are diagnosed with this heterogeneous disease in The Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumours inevitably recur. Currently, there is no gold standard at time of recurrence and treatment options are limited. Unfortunately, the results of dedicated trials with new drugs have been very disappointing. The goal of the project is to obtain the evidence for changing standard of care (SOC) procedures to include whole genome sequencing (WGS) and consequently adapt care guidelines for this specific patient group with very poor prognosis by offering optimal and timely benefit from novel therapies, even in the absence of traditional registration trials for this small volume cancer indication. Methods: The GLOW study is a prospective diagnostic cohort study executed through collaboration of the Hartwig Medical Foundation (Hartwig, a non-profit organisation) and twelve Dutch centers that perform neurosurgery and/or treat GBM patients. A total of 200 patients with a first recurrence of a glioblastoma will be included. Dual primary endpoint is the percentage of patients who receive targeted therapy based on the WGS report and overall survival. Secondary endpoints include WGS report success rate and number of targeted treatments available based on WGS reports and number of patients starting a treatment in presence of an actionable variant. At recurrence, study participants will undergo SOC neurosurgical resection. Tumour material will then, together with a blood sample, be sent to Hartwig where it will be analysed by WGS. A diagnostic report with therapy guidance, including potential matching off-label drugs and available clinical trials will then be sent back to the treating physician for discussing of the results in molecular tumour boards and targeted treatment decision making. Discussion: The GLOW study aims to provide the scientific evidence for changing the SOC diagnostics for patients with a recurrent glioblastoma by investigating complete genome diagnostics to maximize treatment options for this patient group. Trial registration: Identifier: NCT05186064.

Original languageEnglish
Article number233
JournalBMC Medical Genomics
Issue number1
Publication statusPublished - 4 Nov 2022

Bibliographical note

Funding Information:
The GLOW study is funded by OnCode, an independent institute dedicated to understanding cancer and translating research into practice, through their Clinical Proof of Concept Program. Oncode had and has no role in the design nor the collection, analysis and interpretation of the data, nor in the writing of the manuscript. WGS-based diagnostics for this study is facilitated by Hartwig Medical Foundation by offering this service at a reduced fee covering only the data generation costs (mainly reagents and compute costs). Study Protocol has undergone full external peer review by the funding body as part of the peer review process.

Publisher Copyright: © 2022, The Author(s).


Dive into the research topics of 'Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study'. Together they form a unique fingerprint.

Cite this